Fernando Munoz J, Gutierrez-Casbas A, Rodriguez C, Gisbert JP, et al. EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumour necrosis factor-alpha as first- and second-line biologic treatment in Crohn's disease. Gastroenterol Hepatol 2026 Oct 7:502871. doi: 10.1016/j.gastrohep.2026.502871.
PMID: 42843624